ACE+inhibitors+recall

= ACE inhibitors recall =

[|Captopril] [|Enalapril] [|Fosinopril] [|Lisinopril] [|Perindopril] [|Quinapril] [|Ramipril] [|Trandolapril]

ACE inhibitors block conversion of angiotensin I to angiotensin II and also inhibit the breakdown of bradykinin. They reduce the effects of angiotensin II-induced vasoconstriction, sodium retention and aldosterone release. They also reduce the effect of angiotensin on sympathetic nervous activity and as a growth factor.
 * Mode of action**


 * Indications**
 * Hypertension
 * Heart failure
 * Diabetic nephropathy (type 1 diabetes)
 * Prevention of progressive renal failure in patients with persistent proteinuria (>1 g/////day)
 * Asymptomatic left ventricular dysfunction
 * Post MI (acute treatment or in patients with left ventricular dysfunction or heart failure)
 * Reduction of risk of cardiovascular events in specific patients

Advantages for specific ACE inhibitors are claimed based on pharmacokinetic, metabolic or tissue ACE-binding characteristics; however, these do not translate into significant clinical differences. Most (except captopril) maintain an antihypertensive effect for up to 24 hours and can be given once daily. Many are available as combination products with a diuretic (hydrochlorothiazide or indapamide) or a calcium channel blocker. Reserve for patients stabilised on similar doses of single ingredient products.
 * Comparative Information**

Resources
[|AMH - ACE inhibitors]